Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

DOI record: { "DOI": "10.1038/s41429-020-0336-z", "ISSN": [ "0021-8820", "1881-1469" ], "URL": "http://dx.doi.org/10.1038/s41429-020-0336-z", "alternative-id": [ "336" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "21 April 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Revised", "name": "revised", "order": 2, "value": "5 May 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 3, "value": "17 May 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 4, "value": "12 June 2020" }, { "group": { "label": "Compliance with ethical standards", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "The authors declare that they have no conflict of interest." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "family": "Heidary", "given": "Fatemeh", "sequence": "first" }, { "affiliation": [], "family": "Gharebaghi", "given": "Reza", "sequence": "additional" } ], "container-title": "The Journal of Antibiotics", "container-title-short": "J Antibiot", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2020, 6, 12 ] ], "date-time": "2020-06-12T09:04:12Z", "timestamp": 1591952652000 }, "deposited": { "date-parts": [ [ 2023, 5, 20 ] ], "date-time": "2023-05-20T21:34:06Z", "timestamp": 1684618446000 }, "indexed": { "date-parts": [ [ 2024, 5, 13 ] ], "date-time": "2024-05-13T13:24:40Z", "timestamp": 1715606680287 }, "is-referenced-by-count": 225, "issue": "9", "issued": { "date-parts": [ [ 2020, 6, 12 ] ] }, "journal-issue": { "issue": "9", "published-print": { "date-parts": [ [ 2020, 9 ] ] } }, "language": "en", "license": [ { "URL": "https://www.springer.com/tdm", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 6, 12 ] ], "date-time": "2020-06-12T00:00:00Z", "timestamp": 1591920000000 } }, { "URL": "https://www.springer.com/tdm", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 6, 12 ] ], "date-time": "2020-06-12T00:00:00Z", "timestamp": 1591920000000 } } ], "link": [ { "URL": "http://www.nature.com/articles/s41429-020-0336-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "http://www.nature.com/articles/s41429-020-0336-z", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "http://www.nature.com/articles/s41429-020-0336-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "593-602", "prefix": "10.1038", "published": { "date-parts": [ [ 2020, 6, 12 ] ] }, "published-online": { "date-parts": [ [ 2020, 6, 12 ] ] }, "published-print": { "date-parts": [ [ 2020, 9 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.2183/pjab.87.13", "author": "A Crump", "doi-asserted-by": "publisher", "first-page": "13", "journal-title": "Proc Jpn Acad Ser B Phys Biol Sci.", "key": "336_CR1", "unstructured": "Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:13–28. https://doi.org/10.2183/pjab.87.13.", "volume": "87", "year": "2011" }, { "author": "LH Kircik", "first-page": "325", "journal-title": "J Drugs Dermatol", "key": "336_CR2", "unstructured": "Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15:325–32.", "volume": "15", "year": "2016" }, { "DOI": "10.1208/s12248-007-9000-9.", "author": "A Gonzalez Canga", "doi-asserted-by": "publisher", "first-page": "42", "journal-title": "AAPS J.", "key": "336_CR3", "unstructured": "Gonzalez Canga A, Sahagun Prieto AM, Diez Liebana MJ, Fernandez Martinez N, Sierra Vega M, Garcia Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans–a mini-review. AAPS J. 2008;10:42–6. https://doi.org/10.1208/s12248-007-9000-9.", "volume": "10", "year": "2008" }, { "DOI": "10.1016/j.pt.2017.02.004.", "author": "R Laing", "doi-asserted-by": "publisher", "first-page": "463", "journal-title": "Trends Parasitol.", "key": "336_CR4", "unstructured": "Laing R, Gillan V, Devaney E. Ivermectin—old drug, new tricks? Trends Parasitol. 2017;33:463–72. https://doi.org/10.1016/j.pt.2017.02.004.", "volume": "33", "year": "2017" }, { "DOI": "10.1016/j.ijsu.2020.02.034.", "author": "C Sohrabi", "doi-asserted-by": "publisher", "first-page": "71", "journal-title": "Int J Surg.", "key": "336_CR5", "unstructured": "Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–6. https://doi.org/10.1016/j.ijsu.2020.02.034.", "volume": "76", "year": "2020" }, { "DOI": "10.1002/jmv.25678.", "author": "H Lu", "doi-asserted-by": "publisher", "first-page": "401", "journal-title": "J Med Virol", "key": "336_CR6", "unstructured": "Lu H, Stratton CW, Tang Y-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92:401–2. https://doi.org/10.1002/jmv.25678.", "volume": "92", "year": "2020" }, { "DOI": "10.1038/nature12711.", "author": "X-Y Ge", "doi-asserted-by": "publisher", "first-page": "535", "journal-title": "Nature.", "key": "336_CR7", "unstructured": "Ge X-Y, Li J-L, Yang X-L, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503:535–8. https://doi.org/10.1038/nature12711.", "volume": "503", "year": "2013" }, { "DOI": "10.1128/JVI.02582-15.", "author": "X-L Yang", "doi-asserted-by": "publisher", "first-page": "3253", "journal-title": "J Virol.", "key": "336_CR8", "unstructured": "Yang X-L, Hu B, Wang B, et al. Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of severe acute respiratory syndrome coronavirus. J Virol. 2015;90:3253–6. https://doi.org/10.1128/JVI.02582-15.", "volume": "90", "year": "2015" }, { "DOI": "10.1097/JCMA.0000000000000318", "doi-asserted-by": "publisher", "key": "336_CR9", "unstructured": "Lu C-C, Chen M-Y, Chang Y-L. Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc. 2020. https://doi.org/10.1097/JCMA.0000000000000318." }, { "DOI": "10.1016/j.imr.2020.100407.", "author": "L Ang", "doi-asserted-by": "publisher", "first-page": "100407.", "journal-title": "Integr Med Res.", "key": "336_CR10", "unstructured": "Ang L, Lee HW, Choi JY, Zhang J, Soo Lee M. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integr Med Res. 2020;9:100407. https://doi.org/10.1016/j.imr.2020.100407.", "volume": "9", "year": "2020" }, { "author": "R Gharebaghi", "first-page": "e40", "journal-title": "Arch Academic Emerg Med", "key": "336_CR11", "unstructured": "Gharebaghi R, Heidary F, Moradi M, Parvizi M. Metronidazole; a potential novel addition to the COVID-19 treatment regimen. Arch Academic Emerg Med. 2020;8:e40.", "volume": "8", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2020.105944", "doi-asserted-by": "publisher", "key": "336_CR12", "unstructured": "Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020:105944. https://doi.org/10.1016/j.ijantimicag.2020.105944." }, { "DOI": "10.4414/smw.2020.20242.", "author": "R Gharebaghi", "doi-asserted-by": "publisher", "first-page": "w20242.", "journal-title": "Swiss Med Wkly", "key": "336_CR13", "unstructured": "Gharebaghi R, Heidary F. COVID-19 and Iran: swimming with hands tied! Swiss Med Wkly. 2020;150:w20242. https://doi.org/10.4414/smw.2020.20242.", "volume": "150", "year": "2020" }, { "author": "VE Reviglio", "first-page": "71", "journal-title": "Med Hypothesis Disco Innov Ophthalmol", "key": "336_CR14", "unstructured": "Reviglio VE, Osaba M, Reviglio V, Chiaradia P, Kuo IC. COVID-19 and ophthalmology: a new chapter in an old story. Med Hypothesis Disco Innov Ophthalmol. 2020;9:71–3.", "volume": "9", "year": "2020" }, { "DOI": "10.1016/j.antiviral.2020.104787", "doi-asserted-by": "publisher", "key": "336_CR15", "unstructured": "Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020:104787. https://doi.org/10.1016/j.antiviral.2020.104787." }, { "DOI": "10.1016/j.chom.2016.07.004.", "author": "NJ Barrows", "doi-asserted-by": "publisher", "first-page": "259", "journal-title": "Cell Host Microbe", "key": "336_CR16", "unstructured": "Barrows NJ, Campos RK, Powell ST, et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe. 2016;20:259–70. https://doi.org/10.1016/j.chom.2016.07.004.", "volume": "20", "year": "2016" }, { "DOI": "10.1016/j.diagmicrobio.2019.03.012.", "author": "H Ketkar", "doi-asserted-by": "publisher", "first-page": "38", "journal-title": "Diagn Microbiol Infect Dis", "key": "336_CR17", "unstructured": "Ketkar H, Yang L, Wormser GP, Wang P. Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system. Diagn Microbiol Infect Dis. 2019;95:38–40. https://doi.org/10.1016/j.diagmicrobio.2019.03.012.", "volume": "95", "year": "2019" }, { "DOI": "10.1016/j.rvsc.2018.09.005.", "author": "AM Khalil", "doi-asserted-by": "publisher", "first-page": "94", "journal-title": "Res Vet Sci", "key": "336_CR18", "unstructured": "Khalil AM, Abu Samrah HM. In vivo combined treatment of rats with ivermectin and aged garlic extract attenuates ivermectin-induced cytogenotoxicity in bone marrow cells. Res Vet Sci. 2018;120:94–100. https://doi.org/10.1016/j.rvsc.2018.09.005.", "volume": "120", "year": "2018" }, { "DOI": "10.1016/j.virol.2019.10.010.", "author": "W Ji", "doi-asserted-by": "publisher", "first-page": "124", "journal-title": "Virology.", "key": "336_CR19", "unstructured": "Ji W, Luo G. Zika virus NS5 nuclear accumulation is protective of protein degradation and is required for viral RNA replication. Virology. 2020;541:124–35. https://doi.org/10.1016/j.virol.2019.10.010.", "volume": "541", "year": "2020" }, { "DOI": "10.1016/j.antiviral.2013.06.002.", "author": "MYF Tay", "doi-asserted-by": "publisher", "first-page": "301", "journal-title": "Antivir Res.", "key": "336_CR20", "unstructured": "Tay MYF, Fraser JE, Chan WKK, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antivir Res. 2013;99:301–6. https://doi.org/10.1016/j.antiviral.2013.06.002.", "volume": "99", "year": "2013" }, { "DOI": "10.1042/BJ20120150.", "author": "KM Wagstaff", "doi-asserted-by": "publisher", "first-page": "851", "journal-title": "Biochem J.", "key": "336_CR21", "unstructured": "Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443:851–6. https://doi.org/10.1042/BJ20120150.", "volume": "443", "year": "2012" }, { "DOI": "10.1021/acsnano.9b02807.", "author": "B Surnar", "doi-asserted-by": "publisher", "first-page": "11034", "journal-title": "ACS Nano.", "key": "336_CR22", "unstructured": "Surnar B, Kamran MZ, Shah AS, et al. Orally administrable therapeutic synthetic nanoparticle for Zika virus. ACS Nano. 2019;13:11034–48. https://doi.org/10.1021/acsnano.9b02807.", "volume": "13", "year": "2019" }, { "DOI": "10.1016/j.antiviral.2020.104760.", "author": "SNY Yang", "doi-asserted-by": "publisher", "first-page": "104760", "journal-title": "Antivir Res.", "key": "336_CR23", "unstructured": "Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. Antivir Res. 2020;177:104760. https://doi.org/10.1016/j.antiviral.2020.104760.", "volume": "177", "year": "2020" }, { "DOI": "10.1515/hsz-2015-0171.", "author": "FK Kosyna", "doi-asserted-by": "publisher", "first-page": "1357", "journal-title": "Biol Chem.", "key": "336_CR24", "unstructured": "Kosyna FK, Nagel M, Kluxen L, Kraushaar K, Depping R. The importin alpha/beta-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways. Biol Chem. 2015;396:1357–67. https://doi.org/10.1515/hsz-2015-0171.", "volume": "396", "year": "2015" }, { "DOI": "10.1093/jac/dks147.", "author": "E Mastrangelo", "doi-asserted-by": "publisher", "first-page": "1884", "journal-title": "J Antimicrob Chemother", "key": "336_CR25", "unstructured": "Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 2012;67:1884–94. https://doi.org/10.1093/jac/dks147.", "volume": "67", "year": "2012" }, { "DOI": "10.1007/978-1-4939-0348-1_19.", "author": "JE Fraser", "doi-asserted-by": "publisher", "first-page": "301", "journal-title": "Methods Mol Biol", "key": "336_CR26", "unstructured": "Fraser JE, Rawlinson SM, Wang C, Jans DA, Wagstaff KM. Investigating dengue virus nonstructural protein 5 (NS5) nuclear import. Methods Mol Biol. 2014;1138:301–28. https://doi.org/10.1007/978-1-4939-0348-1_19.", "volume": "1138", "year": "2014" }, { "DOI": "10.1155/2016/8043983.", "author": "R Croci", "doi-asserted-by": "publisher", "first-page": "8043983.", "journal-title": "Int J Biomater", "key": "336_CR27", "unstructured": "Croci R, Bottaro E, Chan KWK, et al. Liposomal systems as nanocarriers for the antiviral agent ivermectin. Int J Biomater. 2016;2016:8043983. https://doi.org/10.1155/2016/8043983.", "volume": "2016", "year": "2016" }, { "DOI": "10.1038/s41598-017-18742-8", "author": "SC Atkinson", "doi-asserted-by": "publisher", "first-page": "358.", "journal-title": "Sci Rep.", "key": "336_CR28", "unstructured": "Atkinson SC, Audsley MD, Lieu KG. et al. Recognition by host nuclear transport proteins drives disorder-to-order transition in Hendra virus V. Sci Rep. 2018;8:358. https://doi.org/10.1038/s41598-017-18742-8.", "volume": "8", "year": "2018" }, { "author": "S Azeem", "first-page": "597", "journal-title": "Pak J Pharm Sci", "key": "336_CR29", "unstructured": "Azeem S, Ashraf M, Rasheed MA, Anjum AA, Hameed R. Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Pak J Pharm Sci. 2015;28:597–602.", "volume": "28", "year": "2015" }, { "DOI": "10.1016/j.antiviral.2013.10.004.", "author": "L Lundberg", "doi-asserted-by": "publisher", "first-page": "662", "journal-title": "Antivir Res.", "key": "336_CR30", "unstructured": "Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan equine encephalitis virus replication. Antivir Res. 2013;100:662–72. https://doi.org/10.1016/j.antiviral.2013.10.004.", "volume": "100", "year": "2013" }, { "DOI": "10.1038/s41598-017-17672-9.", "author": "S Shechter", "doi-asserted-by": "publisher", "journal-title": "Sci Rep.", "key": "336_CR31", "unstructured": "Shechter S, Thomas DR, Lundberg L, et al. Novel inhibitors targeting Venezuelan equine encephalitis virus capsid protein identified using in silico structure-based-drug-design. Sci Rep. 2017;7:17705. https://doi.org/10.1038/s41598-017-17672-9.", "volume": "7", "year": "2017" }, { "DOI": "10.1016/j.antiviral.2015.12.012.", "author": "FS Varghese", "doi-asserted-by": "publisher", "first-page": "117", "journal-title": "Antivir Res.", "key": "336_CR32", "unstructured": "Varghese FS, Kaukinen P, Glasker S, et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antivir Res. 2016;126:117–24. https://doi.org/10.1016/j.antiviral.2015.12.012.", "volume": "126", "year": "2016" }, { "DOI": "10.1038/srep23138.", "author": "V Gotz", "doi-asserted-by": "publisher", "journal-title": "Sci Rep.", "key": "336_CR33", "unstructured": "Gotz V, Magar L, Dornfeld D, et al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep. 2016;6:23138. https://doi.org/10.1038/srep23138.", "volume": "6", "year": "2016" }, { "DOI": "10.1007/s00705-015-2653-2.", "author": "YJ Lee", "doi-asserted-by": "publisher", "first-page": "257", "journal-title": "Arch Virol.", "key": "336_CR34", "unstructured": "Lee YJ, Lee C. Ivermectin inhibits porcine reproductive and respiratory syndrome virus in cultured porcine alveolar macrophages. Arch Virol. 2016;161:257–68. https://doi.org/10.1007/s00705-015-2653-2.", "volume": "161", "year": "2016" }, { "DOI": "10.1177/1087057110390360.", "author": "KM Wagstaff", "doi-asserted-by": "publisher", "first-page": "192", "journal-title": "J Biomol Screen", "key": "336_CR35", "unstructured": "Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import. J Biomol Screen. 2011;16:192–200. https://doi.org/10.1177/1087057110390360.", "volume": "16", "year": "2011" }, { "DOI": "10.2478/pjvs-2013-0106.", "author": "A Slonska", "doi-asserted-by": "publisher", "first-page": "749", "journal-title": "Pol J Vet Sci", "key": "336_CR36", "unstructured": "Slonska A, Cymerys J, Skwarska J, Golke A, Banbura MW. Influence of importin alpha/beta and exportin 1 on equine herpesvirus type 1 (EHV-1) replication in primary murine neurons. Pol J Vet Sci. 2013;16:749–51. https://doi.org/10.2478/pjvs-2013-0106.", "volume": "16", "year": "2013" }, { "DOI": "10.1016/j.antiviral.2018.09.010.", "author": "C Lv", "doi-asserted-by": "publisher", "first-page": "55", "journal-title": "Antivir Res.", "key": "336_CR37", "unstructured": "Lv C, Liu W, Wang B, et al. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antivir Res. 2018;159:55–62. https://doi.org/10.1016/j.antiviral.2018.09.010.", "volume": "159", "year": "2018" }, { "DOI": "10.1128/jvi.69.5.2811-2818.1995", "doi-asserted-by": "crossref", "key": "336_CR38", "unstructured": "Berthomme H, Monahan SJ, Parris DS, Jacquemont B, Epstein AL. Cloning, sequencing, and functional characterization of the two subunits of the pseudorabies virus DNA polymerase holoenzyme: evidence for specificity of interaction. J Virol. 1995 May;69(5):2811-8. PubMed PMID: 7707503; PubMed Central PMCID: PMC188975" }, { "DOI": "10.3389/fmicb.2016.00124.", "author": "Y-P Wang", "doi-asserted-by": "publisher", "first-page": "124.", "journal-title": "Front Microbiol", "key": "336_CR39", "unstructured": "Wang Y-P, Du W-J, Huang L-P, et al. The pseudorabies virus DNA polymerase accessory subunit UL42 directs nuclear transport of the holoenzyme. Front Microbiol 2016;7:124. https://doi.org/10.3389/fmicb.2016.00124.", "volume": "7", "year": "2016" }, { "DOI": "10.1016/j.virol.2014.10.013.", "author": "SM Bennett", "doi-asserted-by": "publisher", "first-page": "110", "journal-title": "Virology.", "key": "336_CR40", "unstructured": "Bennett SM, Zhao L, Bosard C, Imperiale MJ. Role of a nuclear localization signal on the minor capsid proteins VP2 and VP3 in BKPyV nuclear entry. Virology. 2015;474:110–6. https://doi.org/10.1016/j.virol.2014.10.013.", "volume": "474", "year": "2015" }, { "DOI": "10.1016/j.virusres.2019.01.010.", "author": "X Wang", "doi-asserted-by": "publisher", "first-page": "80", "journal-title": "Virus Res.", "key": "336_CR41", "unstructured": "Wang X, Lv C, Ji X, Wang B, Qiu L, Yang Z. Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets. Virus Res. 2019;263:80–6. https://doi.org/10.1016/j.virusres.2019.01.010.", "volume": "263", "year": "2019" }, { "DOI": "10.3390/microorganisms8030409", "doi-asserted-by": "publisher", "key": "336_CR42", "unstructured": "Raza S, Shahin F, Zhai W, et al. Ivermectin inhibits bovine herpesvirus 1 DNA polymerase nuclear import and interferes with viral replication. Microorganisms. 2020;8. https://doi.org/10.3390/microorganisms8030409." }, { "key": "336_CR43", "unstructured": "The FDA’s Center for Veterinary Medicine, https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans. Accessed 5 May 2020." }, { "DOI": "10.1208/s12248-007-9000-9", "author": "AG Canga", "doi-asserted-by": "publisher", "first-page": "42", "journal-title": "AAPS J", "key": "336_CR44", "unstructured": "Canga AG, Prieto AM, Liébana MJ, Martínez NF, Vega MS, Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J. 2008;10:42–6.", "volume": "10", "year": "2008" }, { "DOI": "10.1038/ja.2017.11", "author": "A Crump", "doi-asserted-by": "publisher", "first-page": "495", "journal-title": "J Antibiot", "key": "336_CR45", "unstructured": "Crump A. Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. J Antibiot. 2017;70:495–505.", "volume": "70", "year": "2017" } ], "reference-count": 45, "references-count": 45, "relation": {}, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41429-020-0336-z" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "73" }